In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration
暂无分享,去创建一个
Philippe Hantraye | Emmanuel Brouillet | S. Krajewski | S. Humbert | F. Saudou | C. Créminon | E. Brouillet | P. Hantraye | C. Escartin | Carole Escartin | Stan Krajewski | Frédéric Saudou | Sandrine Humbert | Christophe Créminon | Nicolas Bizat | Jean-Michel Hermel | Carine Jacquard | N. Bizat | Carine Jacquard | J. Hermel
[1] Emmanuel Brouillet,et al. The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module , 2002, The Journal of Neuroscience.
[2] S. Harwood,et al. Calpain inhibitor I reduces the activation of nuclear factor-k B and organ injury / dysfunction in hemorrhagic shock , 2000 .
[3] Joseph B. Martin. Huntington's disease , 1984, Neurology.
[4] Changlian Zhu,et al. Synergistic Activation of Caspase-3 by m-Calpain after Neonatal Hypoxia-Ischemia , 2001, The Journal of Biological Chemistry.
[5] Marian DiFiglia,et al. Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.
[6] Peng Li,et al. Direct Cleavage by the Calcium-activated Protease Calpain Can Lead to Inactivation of Caspases* , 2000, The Journal of Biological Chemistry.
[7] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[8] C. Guégan,et al. Specific Caspase Pathways Are Activated in the Two Stages of Cerebral Infarction , 2001, The Journal of Neuroscience.
[9] Françoise Condé,et al. Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.
[10] G. Cole,et al. Activation of Calpain I Converts Excitotoxic Neuron Death into a Caspase-independent Cell Death* , 2000, The Journal of Biological Chemistry.
[11] M. Beal,et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.
[12] B R Rosen,et al. 1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.
[13] S. Krajewski,et al. Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration Induced In Vivo by 3-Nitropropionate: Implications for Huntington's Disease , 2003, The Journal of Neuroscience.
[14] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[15] F. Condé,et al. Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat , 1998, Journal of neurochemistry.
[16] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[17] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[18] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[19] B. Rosen,et al. Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid , 1993, Journal of neurochemistry.
[20] L. Ellerby,et al. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Snyder,et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.
[22] D. Green,et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. , 1999, Blood.
[23] Z. Qin,et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Dash,et al. Caspase activity plays an essential role in long‐term memory , 2000, Neuroreport.
[25] R. Albin,et al. Alternative excitotoxic hypotheses , 1992, Neurology.
[26] M. Beal,et al. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.
[27] M. DiFiglia,et al. Pro-caspase-8 Is Predominantly Localized in Mitochondria and Released into Cytoplasm upon Apoptotic Stimulation* , 2001, The Journal of Biological Chemistry.
[28] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[29] N. Thornberry,et al. The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis , 1996, Nature Structural Biology.
[30] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[31] Elsdon Storey,et al. Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.
[32] Kevin K. W Wang,et al. Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.
[33] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[34] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.